Skip to main content
Top
Published in: Journal of General Internal Medicine 11/2019

01-11-2019 | Atorvastatin | Original Research

Statin Dosing Instructions, Medication Adherence, and Low-Density Lipoprotein Cholesterol: a Cohort Study of Incident Statin Users

Authors: Zachary A. Marcum, PharmD, PhD, Hsiao-Ching Huang, MPH, Robert J. Romanelli, PhD, MPH

Published in: Journal of General Internal Medicine | Issue 11/2019

Login to get access

Abstract

Background

Robust evidence is lacking on optimal timing of statin administration and its impact on patient outcomes.

Objective

This study aims to evaluate among incident statin users the relationship between those prescribed evening vs. daily dosing instructions, medication adherence, and changes in low-density lipoprotein cholesterol (LDL-c).

Design

This is an observational cohort study at Sutter Health, a community-based healthcare system, 2010–2016.

Participants

Patients were ≥ 35 years of age as of the first statin prescription (baseline), with 12 to 36 months of electronic health record activity before and after baseline. Incident use was defined as no statin prescription in 12 months prior to baseline.

Main Measures

Differences in medication adherence (proportion of days covered ≥ 0.80) over 12 months from baseline and mean change in LDL-c between 12 and 24 months from baseline were measured using regression modeling, adjusting for baseline demographics and clinical, prescriber, and statin characteristics.

Key Results

Among 31,252 patients with valid statin prescriptions between 2010 and 2016, 5099 eligible incident statin users (mean age, 63 years) were identified, of whom 53% were prescribed evening and 47% daily dosing instructions. No difference in likelihood of statin adherence over 12 months was observed for evening vs. daily dosing (adjusted odds ratio [OR] 0.90; 95% CI 0.75, 1.08). No differences were observed in mean change in LDL-c (adjusted mean difference 1.42 mg/dL; 95% CI − 1.02, 3.89) or likelihood of attaining LDL-c < 70 mg/dL (adjusted OR 0.83; 95% CI 0.67, 1.04) for evening vs. daily dosing over a mean of 19 months follow-up.

Conclusions

Among incident statin users from a real-world clinical setting, those with daily and evening dosing instructions had similar adherence rates and mean changes in LDL-c. Given potential clinical equipoise for evening and daily dosing, clinicians should consider patient-tailored statin dosing instructions to reduce potentially unnecessary regimen complexity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Salami JA, Warraich H, Valero-Elizondo J, et al. National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the Medical Expenditure Panel Survey. JAMA Cardiol. 2017;2:56–65.CrossRef Salami JA, Warraich H, Valero-Elizondo J, et al. National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the Medical Expenditure Panel Survey. JAMA Cardiol. 2017;2:56–65.CrossRef
2.
go back to reference Gu Q, Paulose-Ram R, Burt VL, Kit BK. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. NCHS Data Brief. 2014;(177):1–8. Gu Q, Paulose-Ram R, Burt VL, Kit BK. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. NCHS Data Brief. 2014;(177):1–8.
3.
go back to reference Parker TS, McNamara DJ, Brown C, et al. Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. Proc Natl Acad Sci U S A. 1982;79:3037–41.CrossRef Parker TS, McNamara DJ, Brown C, et al. Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. Proc Natl Acad Sci U S A. 1982;79:3037–41.CrossRef
4.
go back to reference Plakogiannis R, Cohen H. Optimal low-density lipoprotein cholesterol lowering—morning versus evening statin administration. Ann Pharmacother. 2007;41:106–10.CrossRef Plakogiannis R, Cohen H. Optimal low-density lipoprotein cholesterol lowering—morning versus evening statin administration. Ann Pharmacother. 2007;41:106–10.CrossRef
5.
go back to reference Plakogiannis R, Cohen H, Taft D. Effects of morning versus evening administration of atorvastatin in patients with hyperlipidemia. Am J Health Syst Pharm. 2005;62:2491–4.CrossRef Plakogiannis R, Cohen H, Taft D. Effects of morning versus evening administration of atorvastatin in patients with hyperlipidemia. Am J Health Syst Pharm. 2005;62:2491–4.CrossRef
6.
go back to reference Awad K, Serban MC, Penson P, et al. Effects of morning vs evening statin administration on lipid profile: a systematic review and meta-analysis. J Clin Lipidol. 2017;11:972–85.CrossRef Awad K, Serban MC, Penson P, et al. Effects of morning vs evening statin administration on lipid profile: a systematic review and meta-analysis. J Clin Lipidol. 2017;11:972–85.CrossRef
7.
go back to reference Cilla DD Jr, Gibson DM, Whitfield LP, Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol. 1996;36:604–9.CrossRef Cilla DD Jr, Gibson DM, Whitfield LP, Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol. 1996;36:604–9.CrossRef
8.
go back to reference Saito Y, Yoshida S, Nakaya N, Hata Y, Goto Y. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects: a double-blind comparative study. Arterioscler Thromb. 1991;11:816–26.CrossRef Saito Y, Yoshida S, Nakaya N, Hata Y, Goto Y. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects: a double-blind comparative study. Arterioscler Thromb. 1991;11:816–26.CrossRef
9.
go back to reference Wallace A, Chinn D, Rubin G. Taking simvastatin in the morning compared with evening: randomised clinical trial. BMJ. 2003;327:788.CrossRef Wallace A, Chinn D, Rubin G. Taking simvastatin in the morning compared with evening: randomised clinical trial. BMJ. 2003;327:788.CrossRef
10.
go back to reference Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA-reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol. 2002;54:472–7.CrossRef Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA-reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol. 2002;54:472–7.CrossRef
11.
go back to reference Insull W, Black D, Dujovne C, et al. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Arch Intern Med. 1994;154:2449–55.CrossRef Insull W, Black D, Dujovne C, et al. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Arch Intern Med. 1994;154:2449–55.CrossRef
12.
go back to reference Walter P, Arnet I, Romanens M, Tsakiris DA, Hersberger KE. Pattern of timing adherence could guide recommendations for personalized intake schedules. J Pers Med. 2012;2:267–76.CrossRef Walter P, Arnet I, Romanens M, Tsakiris DA, Hersberger KE. Pattern of timing adherence could guide recommendations for personalized intake schedules. J Pers Med. 2012;2:267–76.CrossRef
13.
go back to reference US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;316:1997–2007.CrossRef US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;316:1997–2007.CrossRef
14.
go back to reference Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;129:S1-S45.CrossRef Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;129:S1-S45.CrossRef
15.
go back to reference Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–16.CrossRef Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–16.CrossRef
16.
go back to reference Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15:728–40.PubMed Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15:728–40.PubMed
17.
go back to reference Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9 and ICD-10 administrative data. Med Care. 2005;43:1130–9.CrossRef Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9 and ICD-10 administrative data. Med Care. 2005;43:1130–9.CrossRef
18.
go back to reference Zocor (simvastatin) [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Coro.; 2010. Zocor (simvastatin) [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Coro.; 2010.
19.
go back to reference Lipitor (atorvastatin) [package insert]. New York, NY: Pfizer Inc.; 2009. Lipitor (atorvastatin) [package insert]. New York, NY: Pfizer Inc.; 2009.
20.
go back to reference Yang Y, Ward-Charlerie S,Dhavie AA, Rupp MT, Green J. Quality and variability of patient directions in electronic prescriptions in the ambulatory care setting. J Manag Care Spec Pharm. 2018;24:691–9.PubMed Yang Y, Ward-Charlerie S,Dhavie AA, Rupp MT, Green J. Quality and variability of patient directions in electronic prescriptions in the ambulatory care setting. J Manag Care Spec Pharm. 2018;24:691–9.PubMed
21.
go back to reference Obońska K, Kasprzak M, Sikora J, et al. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial. Trials. 2017;18:316.CrossRef Obońska K, Kasprzak M, Sikora J, et al. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial. Trials. 2017;18:316.CrossRef
22.
go back to reference Go AS, Fan D, Sung SH, et al. Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: the KP CHAMP study. Am Heart J. 2017;194:25–38.CrossRef Go AS, Fan D, Sung SH, et al. Contemporary rates and correlates of statin use and adherence in nondiabetic adults with cardiovascular risk factors: the KP CHAMP study. Am Heart J. 2017;194:25–38.CrossRef
23.
go back to reference Stirratt MJ, Curtis JR, Danila MI, Hansen R, Miller MJ, Gakumo CA. Advancing the science and practice of medication adherence. J Gen Intern Med. 2018;33:216–22.CrossRef Stirratt MJ, Curtis JR, Danila MI, Hansen R, Miller MJ, Gakumo CA. Advancing the science and practice of medication adherence. J Gen Intern Med. 2018;33:216–22.CrossRef
24.
go back to reference Ofori-Asenso R, Jakhu A, Curtis AJ, et al. A systematic review and meta-analysis of the factors associated with nonadherence and discontinuation of statins among people aged ≥65 years. J Gerontol A Biol Sci Med Sci. 2018;73:798–805.CrossRef Ofori-Asenso R, Jakhu A, Curtis AJ, et al. A systematic review and meta-analysis of the factors associated with nonadherence and discontinuation of statins among people aged ≥65 years. J Gerontol A Biol Sci Med Sci. 2018;73:798–805.CrossRef
25.
go back to reference Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526–34.CrossRef Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158:526–34.CrossRef
26.
go back to reference Yusuf S. Why do people not take life-saving medications? The case of statins. Lancet. 2016;388:943–5.CrossRef Yusuf S. Why do people not take life-saving medications? The case of statins. Lancet. 2016;388:943–5.CrossRef
27.
go back to reference Grundy SM. Statin discontinuation and intolerance: the challenge of lifelong therapy. Ann Intern Med. 2013;158:562–3.CrossRef Grundy SM. Statin discontinuation and intolerance: the challenge of lifelong therapy. Ann Intern Med. 2013;158:562–3.CrossRef
28.
go back to reference Kim SH, Kim MK, Seo HS, et al. Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: a randomized, double-blind, multicenter phase III trial. Clin Ther. 2013;35:1350–60.CrossRef Kim SH, Kim MK, Seo HS, et al. Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: a randomized, double-blind, multicenter phase III trial. Clin Ther. 2013;35:1350–60.CrossRef
29.
go back to reference Kruse W, Nikolaus T, Rampmaier J, Weber E, Schlierf G. Actual versus prescribing timing of lovastatin doses assessed by electronic compliance monitoring. Eur J Clin Pharmacol. 1993; 45:211–5.CrossRef Kruse W, Nikolaus T, Rampmaier J, Weber E, Schlierf G. Actual versus prescribing timing of lovastatin doses assessed by electronic compliance monitoring. Eur J Clin Pharmacol. 1993; 45:211–5.CrossRef
30.
go back to reference Guglielmi V, Bellia A, Pecchioli S, et al. Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: a real-world evidence study in primary care. Atherosclerosis. 2017;263:36–41.CrossRef Guglielmi V, Bellia A, Pecchioli S, et al. Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: a real-world evidence study in primary care. Atherosclerosis. 2017;263:36–41.CrossRef
31.
go back to reference Franklin JM, Krumme AA, Tong AY, et al. Association between trajectories of statin adherence and subsequent cardiovascular events. Pharmacoepidemiol Drug Saf. 2015;24:1105–13.CrossRef Franklin JM, Krumme AA, Tong AY, et al. Association between trajectories of statin adherence and subsequent cardiovascular events. Pharmacoepidemiol Drug Saf. 2015;24:1105–13.CrossRef
Metadata
Title
Statin Dosing Instructions, Medication Adherence, and Low-Density Lipoprotein Cholesterol: a Cohort Study of Incident Statin Users
Authors
Zachary A. Marcum, PharmD, PhD
Hsiao-Ching Huang, MPH
Robert J. Romanelli, PhD, MPH
Publication date
01-11-2019
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 11/2019
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-019-05180-7

Other articles of this Issue 11/2019

Journal of General Internal Medicine 11/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.